Episode
Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685
- Podcast
- Biohacking News by Zestology
- Published
- Mar 30, 2026
- Duration seconds
- 1970
- Processing state
not_requested- Canonical source
- https://zestology.libsyn.com/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685
Actions
POST https://stenobird.com/v1/public/podcasts/biohacking-news-by-zestology-173365/episodes/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biohacking-news-by-zestology-173365/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Yet more GLP1 news this week. People regain on average 60% of their lost weight within a year of stopping GLP-1 drugs — and the regained weight may be disproportionately fat rather than muscle. So are a tool that biohackers have known about for years - CGMs - the answer? Sharam Fouladgar-Mercer is the co-founder of Signos, the first ever FDA-cleared glucose system for weight management. Follow Sharam Fouladgar-Mercer on LinkedIn.